Malaria is both preventable and treatable, yet this mosquito-borne infectious disease takes the life of a child every 30 seconds. It is a major health burden in more than 100 countries and poses a constant threat to economic stability in endemic regions. Fighting malaria faces two challenges: transmission patterns vary from location to location, complicating efforts to target the disease, and resistance to antimalarial drugs is spreading rapidly.
CDDEP researchers participate in the Malaria Atlas Project, a spatial database that combines medical intelligence and climate data to track malaria transmission and prevalence. Using a bioeconomic model of malaria transmission and evolution of drug resistance to define optimal treatment strategies, they are developing a strategic plan to tackle the disease. Regional, cross-border coordination will be essential to slow both transmission and the spread of drug-resistant strains. 
ACTs, artemisinin-based combination therapies, are effective and can limit the development of further resistance to a valuable antimalarial, but they are expensive. Applying tools from economics, CDDEP researchers helped develop an innovative financing arrangement, the Affordable Medicines Facility–malaria—a global subsidy to make these drugs affordable while addressing the public goods problem of resistance.


This article examines what is known about how resistance to antimalarial drugs emerges and spreads, and reviews various strategies for controlling the spread of resistance.


Rising numbers of drug-resistant pathogens pose a grave concern for the global community. In May, the World Health Organization highlighted the dangers antimicrobial resistance presents on a...


This graphic, from a recent paper reviewing current knowledge of antimalarial drug resistance, illustrates nine stages in the life cycle of the malaria parasite. The paper describes the cycle thus:
The maps show the geographic spread of K. penumoniae isolates exhibiting resistance to third-generation cephalosporins (G3CRKP) and carbapenems (CRKP) between 1999 and 2010. Resistant phenotypes were more endemic in the Eastern part of the country, particularly the Middle and South Atlantic Census divisions.